Lewes, DE -- (SBWire) -- 10/02/2013 --LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Antares Pharma Inc (NASDAQ:ATRS), WisdomTree Investments, Inc. (NASDAQ:WETF), Flextronics International Ltd. (NASDAQ:FLEX), Amarin Corporation plc (ADR) (NASDAQ:AMRN).

Antares Pharma Inc (NASDAQ:ATRS), increased7.39% and closed at $4.36 on a traded volume of 3.15 million shares, in comparison to 1.04 million shares of average trading volume. So far this year, the stock is up over 32.12%.

The company has a total market capitalization of $554.41million and its total outstanding shares are 127.16million.

Will ATRS Continue To Move Higher? Find Out Here

Antares Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies, and topical gel-based medicines worldwide.

WisdomTree Investments, Inc. (NASDAQ:WETF), soared7.15% and closed at $12.43 on a traded volume of 3.06 million shares, whereas its average trading volume is 1.33 million shares. In the last three months, the stock is up5.52%. The Intra-day range for the stock is $11.62 and $12.65.

Will WETF Continue To Move Higher? Find Out Here

WisdomTree Investments, Inc., through its subsidiaries, operates as an exchange-traded funds (ETFs) sponsor and asset manager. It offers ETFs in equities, currency, fixed income, and alternatives asset classes.

Flextronics International Ltd. (NASDAQ:FLEX), jumped up1.21 % and closed at $9.20. So far in three months, the stock is up 17.8%. The 52-week range for the stock is $5.47 and $9.70 and during the previous trading session it marked$9.21 as its highest price. The stock initially exchanged hands with a price of $9.05 and the overall traded volume that day was 2.97million shares.

Will FLEX Continue To Move Higher? Find Out Here

Flextronics International Ltd. provides design and manufacturing services to original equipment manufacturers (OEMs) worldwide.

Amarin Corporation plc (ADR) (NASDAQ:AMRN) after opening its shares at the price of $6.36, jumped up3.01% to close the day at $6.51. The stock ended on a traded volume of 2.96 million shares, in comparison to 4.67 million shares of average trading volume. The 52-week range for the stock is $5.12 and $12.96 and during the previous trading session the stock scored the highest price of $6.52. It started the day at $6.36.

Why Should Investors Buy AMRN After The Recent Gain? Just Go Here and Find Out.

Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company’s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia.

About LeadingStockAlerts:
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.

Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.

Disclaimer:
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/